Table I.
Global incidence ranks of neoplasms in 2017
| Cause∗ | Number of new cases (2017) | Percent change (1990-2017) | 2017 Incidence rank |
|---|---|---|---|
| Other benign and in situ neoplasms | 9,714,953 | 42.8% | 1 |
| Skin cancer: basal cell carcinoma | 5,884,759 | 77.4% | 2 |
| Lung cancer | 2,163,132 | 100.4% | 3 |
| Breast cancer | 1,960,682 | 123.1% | 4 |
| Colorectal cancer | 1,833,451 | 121.9% | 5 |
| Skin cancer: squamous cell carcinoma | 1,778,829 | 309.7% | 6 |
| Prostate cancer | 1,334,315 | 179.1% | 7 |
| Stomach cancer | 1,220,662 | 41.2% | 8 |
| Benign and in situ intestinal neoplasms | 1,010,854 | 60.9% | 9 |
| Other malignant neoplasms | 715,546 | 132.0% | 10 |
| Cervical cancer | 601,186 | 44.5% | 11 |
| Lymphoma | 487,964 | 135.9% | 12 |
| Bladder cancer | 473,800 | 90.1% | 13 |
| Esophageal cancer | 472,525 | 52.3% | 14 |
| Pancreatic cancer | 447,665 | 129.1% | 15 |
| Uterine cancer | 406,793 | 121.6% | 16 |
| Brain cancer | 405,218 | 108.4% | 17 |
| Liver cancer (due to hepatitis B) | 403,964 | 83.8% | 18 |
| Kidney cancer | 393,043 | 89.6% | 19 |
| Lip and oral cavity cancer | 389,760 | 109.6% | 20 |
| Melanoma | 308,684 | 161.3% | 21 |
| Benign and in situ cervical and uterine neoplasms | 299,385 | 14.6% | 22 |
| Ovarian cancer | 286,127 | 88.1% | 23 |
∗
Benign and in situ neoplasms: International Statistical Classification of Diseases and Related Health Problems, Tenth Revision ([ICD-10] codes D00-D49).